Similar articles

• Lipid and apolipoprotein levels in patients with ischaemic heart disease. A comparative study in Plzen and Moscow.

  Steinerová A, Perova NV, Metel'skaya VA, Topolcan O, Karlícek V, Polívková V. Steinerová A, et al. Cor Vasa. 1989;31(4):257-63. Cor Vasa. 1989. PMID: 2509134
• [Effect of apolipoprotein E gene plasma levels of lipids, lipoproteins, apolipoproteins and its relation with coronary heart disease].

  Zhu T, Wang Z, Zhao S. Zhu T, et al. Hunan Yi Ke Da Xue Xue Bao. 1998;23(2):149-51. Hunan Yi Ke Da Xue Xue Bao. 1998. PMID: 10681829 Chinese.
• Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.

  Connelly PW, Poapst M, Davignon J, Lussier-Cacan S, Reeder B, Lessard R, Hegele RA, Csima A. Connelly PW, et al. Can J Cardiol. 1999 Apr;15(4):409-18. Can J Cardiol. 1999. PMID: 10322250
• Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias.

  Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Alaupovic P, et al. Clin Chem. 1988;34(8B):B13-27. Clin Chem. 1988. PMID: 3042196 Review. No abstract available.
• Effects of weight reduction, exercise, and diet modification on lipids and apolipoproteins A-1 and B in severely obese persons.

  Fachnie JD, Foreback CC. Fachnie JD, et al. Henry Ford Hosp Med J. 1987;35(4):216-20. Henry Ford Hosp Med J. 1987. PMID: 3329171 Review. No abstract available.